Notwithstanding encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from PBMs. Such organizations are often building limitations to reimbursement, including steep price restrictions and app